Kiniksa Pharmaceuticals International Newsroom

J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsNov 5 07:31 ET

Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow JonesOct 30 11:08 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaOct 30 10:58 ET

Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35

Moomoo NewsOct 30 08:33 ET

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsOct 30 06:35 ET

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsOct 10 08:36 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaSep 13 09:05 ET

Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40

Moomoo NewsSep 13 05:33 ET

J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39

Moomoo NewsSep 12 08:32 ET

Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsJul 24 08:33 ET

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35

Moomoo NewsJul 24 05:32 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaJul 23 12:56 ET

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

BenzingaJul 23 12:55 ET

Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsJul 23 12:31 ET

Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating

MT NewswiresJul 23 10:33 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaMay 3 11:50 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaMay 1 10:48 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaApr 24 13:40 ET

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects

TipRanksApr 24 05:51 ET

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution

TipRanksApr 23 11:11 ET